Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347176 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT02347176: Completed Phase 2 study, sponsored by MedImmune.
NCT02347176 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 204 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02347176, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
Primary Outcome
EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The maximum total score is 72, with higher values indicating more severe disease. The data presented here is Adjusted mean change after excluding the data from participants who took prohibited medications.
Interventions
- OTHER Placebo
- BIOLOGICAL Tralokinumab Dose 1
- BIOLOGICAL Tralokinumab Dose 2
- BIOLOGICAL Tralokinumab Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2015-01-23 |
| Est. Completion | 2016-02-05 |
| Phase | Phase 2 |
What the finished NCT02347176 record still lists
NCT02347176 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02347176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02347176 about?
NCT02347176 is a clinical study titled "Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis". The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
What is the current status of trial NCT02347176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2015-01-23. Estimated completion is 2016-02-05.
What interventions are being tested in trial NCT02347176?
The interventions under investigation include: Placebo (OTHER), Tralokinumab Dose 1 (BIOLOGICAL), Tralokinumab Dose 2 (BIOLOGICAL), Tralokinumab Dose 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02347176?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02347176's enrollment target sits among peer trials
204 299th of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI